DEF: iRhythm 2026 Proxy Statement: Strategic Growth & Governance

iRhythm Holdings, Inc. announces its 2026 Annual Meeting of Stockholders to vote on director elections, a new equity incentive plan, and corporate governance amendments.

Summary

• The 2026 Annual Meeting will be held virtually on May 27, 2026, at 9:00 a.m. Pacific Time.
• Key proposals include electing nine directors, adopting the 2026 Equity Incentive Plan (reserving 1,690,000 shares), and removing a pass-through voting provision from the subsidiary's certificate of incorporation.
• Full-year 2025 revenue reached $747.1 million, a 26.2% year-over-year increase.
• The company achieved its first-ever positive quarterly GAAP net income in Q4 2025 and its first full year of positive free cash flow.
• Adjusted EBITDA for 2025 was $68.9 million, or 9.2% of revenue.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong, positive filing, highlighting the company's successful transition to profitability and cash flow generation while maintaining robust growth.

Positives

• Achieved 26.2% year-over-year revenue growth in 2025, totaling $747.1 million.
• Delivered first full year of positive free cash flow in company history.
• Achieved first-ever positive quarterly GAAP net income in Q4 2025.
• Gross margin improved by 170 basis points compared to 2024.
• Successfully completed all FDA remediation activities.

Negatives

• Reported a net loss of $44.55 million for the full year 2025.
• Continued reliance on stock-based compensation, which totaled $88.28 million in 2025.
• Ongoing regulatory and compliance challenges, necessitating specific remediation efforts.

Risks

• Potential material impact from cybersecurity threats, including data breaches or service interruptions.
• Risks associated with regulatory compliance and the potential for future FDA observations.
• Intense competition in the digital healthcare and cardiac monitoring market.
• Dependence on the Zio System and the ability to maintain market share in long-term continuous monitoring.

Future Outlook

The company aims to build on 2025 momentum by advancing growth pillars, including the next-generation Zio MCT (21-day wear), expanding international presence, and deepening EHR integration to drive prescribing consistency.

Management Comments

• Management believes the 2025 compensation outcomes appropriately reflect the exceptional results delivered by the leadership team.
• The company is committed to operational discipline and maintaining the momentum that drove 2025 performance.

Industry Context

StockSavvy.ai notes that iRhythm is successfully transitioning from a high-growth, loss-making startup phase to a more mature, operationally disciplined medical technology company, aligning with broader industry trends of prioritizing profitability and cash flow alongside innovation.

Comparison to Industry Standards

• Revenue growth of 26.2% remains strong relative to the broader medical device sector.
• The shift toward profitability and positive free cash flow aligns with current investor demands for sustainable growth in the med-tech space.
• The company's 50/50 RSU/PSU equity mix is consistent with market-leading practices for executive compensation.

Corporate Governance

Legal Proceedings

• The company is involved in ongoing intellectual property litigation, specifically patent litigation brought by Welch Allyn, Inc. and Bardy Diagnostics, Inc.

Related Party Transactions

• None disclosed beyond standard executive and director compensation.

Stakeholder Impact

• Shareholders are asked to vote on significant governance and equity plan changes.
• Employees benefit from the proposed 2026 Equity Incentive Plan for retention.
• Customers and patients benefit from continued innovation and product pipeline expansion.

Next Steps

• Hold 2026 Annual Meeting of Stockholders on May 27, 2026.
• Implement 2026 Equity Incentive Plan if approved.
• File Amended and Restated Certificate of Incorporation if approved.

Key Dates

Recommendation

While the company is showing strong operational improvement and a path to profitability, the stock price has already seen significant appreciation (97% in 2025), and the company faces ongoing regulatory and competitive risks that warrant a cautious hold approach.

Keywords

iRhythm, IRTC, digital healthcare, cardiac monitoring, proxy statement, equity incentive plan, corporate governance